<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759603</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0208</org_study_id>
    <secondary_id>NCI-2012-01674</secondary_id>
    <nct_id>NCT00759603</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of lenalidomide and
      rituximab can help to control Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic
      Lymphoma (SLL) in patients who have already received therapy. The safety of this drug
      combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Lenalidomide is designed to change the body's immune system and may also interfere with the
      development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
      may decrease the growth of cancer cells.

      Rituximab is designed to bind to a protein, called cluster of differentiation antigen 20
      (CD20), that is on the surface of the leukemia cells, allowing the leukemia cells to be
      destroyed by the immune system.

      Drug Administration:

      If you are found to be eligible to take part in this study, you will receive rituximab
      through a needle into your vein 1 time a week in Cycle 1. You will not receive rituximab
      during Cycle 2, but you will continue to take lenalidomide.You will receive a dose of
      rituximab by vein on Day 1 of Cycles 3-12. Your first dose of rituximab will be given over
      6-8 hours. If the first dose is well tolerated, you may receive the next doses over 2-4
      hours. If the doctor thinks it is needed, the next doses may given over a longer time.

      On Day 9 of Cycle 1, you will begin taking lenalidomide by mouth once a day. You will then
      take lenalidomide once a day, every day.

      The dose and schedule of lenalidomide may change depending on the side effects you may
      experience. You should swallow lenalidomide capsules whole with a glass (8 ounces) water at
      the same time each day. Do not break, chew, or open the capsules. If you miss a dose of
      lenalidomide, take it as soon as you remember on the same day. If you miss a dose, it should
      NOT be made up on another day.

      Each study cycle is 4 weeks.

      Study Visits:

      Once a week during the first 5 weeks, blood (about 1 tablespoon) will be drawn for routine
      tests.

      After the first 5 weeks, blood (about 1 tablespoon) will be drawn for routine tests every 2
      weeks until the doctor thinks your dose of lenalidomide will not change. After this, blood
      (about 1 tablespoon) will then be drawn every 4 weeks for routine tests.

      At the end of Cycles 3, 6, and 12, you will have a bone marrow biopsy and aspirate to check
      the status of the disease. Blood (about 1 tablespoon) will be drawn for routine blood tests.

      If you stay on study past 12 cycles, once every 6 cycles (Cycles 18, 24, 30, and so on), you
      will have a bone marrow biopsy and aspirate to check the status of the disease. Blood (about
      1 tablespoon) will be drawn for routine blood tests.

      Blood (about 1 tablespoon) will be drawn more often if the dose of lenalidomide needs to be
      changed or if you experience intolerable side effects.

      Pregnancy Testing:

      Women who are able to become pregnant must have a negative urine or blood (less than 1
      teaspoon) pregnancy test 10-14 days and 24 hours before the first dose of lenalidomide, even
      if they have not had a menstrual period due to treatment of the disease or had only 1
      menstrual period in the past 24 months.

      If you have regular or no menstrual cycles, you will then have a urine or blood (less than 1
      teaspoon) pregnancy test every week for the first 4 weeks, then every 4 weeks while taking
      lenalidomide, again as soon as you have been taken off of lenalidomide therapy, and then 28
      days after you have stopped taking lenalidomide.

      If you have irregular menstrual cycles, you will have urine or blood (less than 1 teaspoon)
      pregnancy test every week for the first 4 weeks, then every 2 weeks while taking
      lenalidomide, again as soon as you have been taken off of lenalidomide therapy, and then at
      14 days and 28 days after you have stopped taking lenalidomide.

      Length of Study:

      You will be on study treatment for about 1 year. You will be taken off study early if you
      experience intolerable side effects or the disease gets worse.

      If the doctor thinks you are benefiting, you may be able to continue taking the study
      treatment. If you continue, you will follow the same schedule of dosing and study visit
      schedule.

      This is an investigational study. Lenalidomide and rituximab are FDA approved and
      commercially available. Lenalidomide is approved for the treatment of multiple myeloma and
      some myelodysplastic syndromes. Rituximab is approved for the treatment of chronic
      lymphoproliferative disorders and non-Hodgkin's lymphoma. The combination of these drugs to
      treat CLL and SLL is investigational.

      Up to 60 patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group Guidelines</measure>
    <time_frame>Responses assessed after 12 cycles, up to 48 weeks with interim assessments performed after 3, 6 and 12 cycles.</time_frame>
    <description>Complete response: Absence lymphadenopathy, hepatomegaly or splenomegaly &amp; constitutional symptoms; Normal complete blood count (CBC) exhibited by polymorphonuclear leukocytes&gt;1500/µL, platelets&gt;100,000/µL, hemoglobin&gt;11.0 g/dL (untransfused); lymphocyte count &lt;5,000/µL; Bone marrow aspirate &amp; biopsy normocellular for age with &lt;30% nucleated cells lymphocytes; Absence Lymphoid nodules. Fulfillment CR criteria after induction with exception of treatment related persistent cytopenia &amp; bone marrow lymphoid nodules both considered partial response; Partial response: Requires 50% decrease in peripheral lymphocytes from pre-treatment, 50% reduction in lymphadenopathy, &amp;/or 50% reduction in splenomegaly/hepatomegaly for 2+ months from therapy completion. Additionally one following from pre-treatment: Polymorphonuclear leukocytes 1,500/µL or 50% improvement; Platelets&gt;100,000/µL or 50% improvement; Hemoglobin&gt;11.0 g/dL (untransfused) or 50% improvement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.</description>
    <arm_group_label>Lenalidomide + Rituximab</arm_group_label>
    <other_name>Revlimid ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Dose of 375 mg/m^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.</description>
    <arm_group_label>Lenalidomide + Rituximab</arm_group_label>
    <other_name>Rituxan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
             with active disease.

          2. Patients must be age 18 or over at the signing of consent and must understand and
             voluntarily sign an informed consent.

          3. Prior treatment with purine analog based chemotherapy or chemoimmunotherapy.

          4. Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance
             status of 0-2.

          5. Adequate renal function indicated by serum creatinine less or equal to 2 mg/dl.
             Adequate hepatic function indicated as total bilirubin less or equal to 2 mg/dl and
             ALT less or equal to two times the upper limit of normal.

          6. Disease free of prior malignancies for 3 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix
             or breast. Patients with malignancies with indolent behavior such as prostate cancer
             treated with radiation or surgery can be enrolled in the study as long as they have a
             reasonable expectation to have been cured with the treatment modality received.

          7. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test (sensitivity of at least 50 milli-International unit (mIU/mL) 10-14 days prior to
             starting lenalidomide. A female of childbearing potential is a sexually mature woman
             who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
             naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at
             any time in the preceding 24 consecutive months).

          8. Continued from Criteria #7. FCBP must either commit to continued abstinence from
             heterosexual intercourse or begin TWO acceptable methods of birth control, one highly
             effective method and one additional effective method AT THE SAME TIME, at least 28
             days before she starts talking lenalidomide. FCBP must also agree to ongoing pregnancy
             testing.

          9. Continued from Criteria #8: Men must agree to use a latex condom during sexual contact
             with a FCBP even if they have had a successful vasectomy. All patients must be
             counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal
             exposure.

         10. Men must agree not to father a child. They must agree to use a latex condom during
             sexual contact with females of childbearing potential while participating in the study
             and for at least 28 days following discontinuation from the study even if he has
             undergone a vasectomy. They will be warned that sharing study drug is prohibited and
             will be counseled about pregnancy precautions and potential risks of fetal exposure.
             They must agree to abstain from donating blood, semen, or sperm during study
             participation and for at least 28 days after discontinuation from the study.

         11. Continued from Criteria #10: Counseling about the requirement for latex condom use
             during sexual contact with females of childbearing potential and the potential risks
             of fetal exposure must be conducted at a minimum of every 28 days. During counseling,
             subjects must be reminded not to share study drug and to not donate blood, sperm, or
             semen (during study participation and for 28 days following discontinuation from the
             study).

        Exclusion Criteria:

          1. Known sensitivity to lenalidomide or other thalidomide derivatives or rituximab.

          2. Documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).

          3. Known positivity for HIV or active hepatitis (B or C).

          4. Pregnant or breast feeding females.

          5. History of tuberculosis treated within the last five years or recent exposure to
             tuberculosis.

          6. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             places the subject at unacceptable risk if he/she were to participate in the study.

          7. Patients with a recent history of deep vein thrombosis (DVT) or pulmonary embolus
             (PE), in the six months prior to enrollment are not eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Ferrajoli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>July 27, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2015</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>SLL</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 22, 2008 to November 02, 2009. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>One of the 60 participants enrolled was excluded from the trial before any treatment assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide + Rituximab</title>
          <description>Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide + Rituximab</title>
          <description>Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="42" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group Guidelines</title>
        <description>Complete response: Absence lymphadenopathy, hepatomegaly or splenomegaly &amp; constitutional symptoms; Normal complete blood count (CBC) exhibited by polymorphonuclear leukocytes&gt;1500/µL, platelets&gt;100,000/µL, hemoglobin&gt;11.0 g/dL (untransfused); lymphocyte count &lt;5,000/µL; Bone marrow aspirate &amp; biopsy normocellular for age with &lt;30% nucleated cells lymphocytes; Absence Lymphoid nodules. Fulfillment CR criteria after induction with exception of treatment related persistent cytopenia &amp; bone marrow lymphoid nodules both considered partial response; Partial response: Requires 50% decrease in peripheral lymphocytes from pre-treatment, 50% reduction in lymphadenopathy, &amp;/or 50% reduction in splenomegaly/hepatomegaly for 2+ months from therapy completion. Additionally one following from pre-treatment: Polymorphonuclear leukocytes 1,500/µL or 50% improvement; Platelets&gt;100,000/µL or 50% improvement; Hemoglobin&gt;11.0 g/dL (untransfused) or 50% improvement.</description>
        <time_frame>Responses assessed after 12 cycles, up to 48 weeks with interim assessments performed after 3, 6 and 12 cycles.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Rituximab</title>
            <description>Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group Guidelines</title>
          <description>Complete response: Absence lymphadenopathy, hepatomegaly or splenomegaly &amp; constitutional symptoms; Normal complete blood count (CBC) exhibited by polymorphonuclear leukocytes&gt;1500/µL, platelets&gt;100,000/µL, hemoglobin&gt;11.0 g/dL (untransfused); lymphocyte count &lt;5,000/µL; Bone marrow aspirate &amp; biopsy normocellular for age with &lt;30% nucleated cells lymphocytes; Absence Lymphoid nodules. Fulfillment CR criteria after induction with exception of treatment related persistent cytopenia &amp; bone marrow lymphoid nodules both considered partial response; Partial response: Requires 50% decrease in peripheral lymphocytes from pre-treatment, 50% reduction in lymphadenopathy, &amp;/or 50% reduction in splenomegaly/hepatomegaly for 2+ months from therapy completion. Additionally one following from pre-treatment: Polymorphonuclear leukocytes 1,500/µL or 50% improvement; Platelets&gt;100,000/µL or 50% improvement; Hemoglobin&gt;11.0 g/dL (untransfused) or 50% improvement.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collected through 12 cycles of 28-days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide + Rituximab</title>
          <description>Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hemolytic anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Evan's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Left leg swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cardiac other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Perianal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary infection RSV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective surgery, right knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tumor flare</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Penumonia/bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic or laboratory</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neurologic other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated serum creatinine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alessandra Ferrajoli, MD/Professor, Leukemia</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

